

Product Update

palonosetron 500microgram soft capsules (Aloxi®) (No: 838/13)
Sinclair IS Pharma

11 January 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

palonosetron soft capsules (Aloxi®) is accepted for use within NHS Scotland.

Indication under review: prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.

At recommended licensed doses the soft capsule formulation has been shown to be clinically non-inferior to the intravenous formulation and is cost neutral.

SMC has previously accepted palonosetron intravenous injection for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

*This assessment is based on data submitted by the applicant company up to and including **14 November 2012.***

Chairman
Scottish Medicines Consortium